Pfizer to Acquire ADC Cancer Specialist Seagen for US$43 B
By Lucy Haggerty
Pharma Deals Review: Vol 2023 Issue 3 (Table of Contents)
Published: 15 Mar-2023
DOI: 10.3833/pdr.v2023.i3.2770 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In the biggest M&A deal since 2019, Pfizer has agreed to acquire Seagen for US$299 in cash per Seagen share, representing a total enterprise value of US$43 B and a 33% premium to Seagen’s closing price the day prior to the announcement...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS